Centene Corporation (NYSE:CNC) Poised To Stabilize Earnings Momentum Amid Operational Repositioning

Centene presents a mixed fundamental profile: strong cash generation and high free-cash-flow yield offset by compressed margins and falling QoQ earnings; technicals signal range-bound action with a short-term risk of a pullback.

Recent News

On June 10, 2026 Home State Health and the Centene Foundation opened a $750,000 grant round for Missouri organizations addressing social drivers of health, with applications open through July 10 and awards expected in August. On July 28, 2026 Centene announced a Board change: Kenneth A. Burdick retired and Paul J. Diaz joined the Board, effective July 28, 2026. Centene and subsidiaries continued community investments in early August, including targeted disaster relief and local medical-respite program support.

Technical Analysis

ADX sits at 17.52, indicating no dominant trend and therefore increased probability of range-bound price behavior over the near term.

DI+ shows a peak-and-reverse, which reads as bearish; DI‑ also shows a peak-and-reverse, which reads as bullish. The simultaneous peak-and-reverse on both directional indicators plus a sub-20 ADX suggests directional signals conflict and reinforce sideways action rather than a clear breakout.

MACD registers 0.21 with a dip-and-reversal pattern (MACD increasing) but remains below its signal line (MACD signal 0.28), so momentum has turned constructive yet lacks a confirmed bullish cross; momentum remains tentative until MACD clears the signal line.

MRO at 12.92 sits positive, implying the current price sits above a short-term target and therefore carries potential downward pressure despite other constructive elements; treat this as near-term overextension risk against the longer-term valuation.

RSI at 53.6 and decreasing points to neutral-to-fading upside momentum rather than a fresh rally; the indicator supports a consolidation view while momentum cools.

Price sits around $65.47, inside the 20-day Bollinger band range (lower ~$64.43, upper ~$66.63) and above the 200-day average ($49.29), so shorter-term mean reversion within the upper-$60s and support near the mid-$60s appears most likely.

 


Fundamental Analysis

Revenue growth shows a strong annual expansion: revenue growth year-over-year at 59.89% and revenue growth quarter-over-quarter at 15.54%, supporting top-line momentum. Total revenue reached $53,579,000,000 for the period ending 2026-06-30.

Margins contracted: operating margin equals 2.236% and EBIT margin equals 3.059%; EBIT margin declined QoQ by 32.49% and YoY by 18.19%, leaving margins below the industry peer mean (EBIT margin mean 7.683%) and below the industry peer median (4.462%) but above the industry peer low. Margin compression represents a material near-term headwind to earnings power.

Earnings and cash flow show divergence: reported EPS came in at $2.51 versus an estimate of $1.08, for an EPS surprise of +132.41%, while net income from continuing operations totaled $1,087,000,000. Operating cash flow totaled $3,590,000,000 and free cash flow reached $3,416,000,000; free-cash-flow yield equals 11.49%, meaning cash generation materially outpaces the industry peer mean free-cash-flow yield (2.071%).

Returns and balance-sheet metrics: return on equity equals 4.84%, slightly above the industry peer mean (4.35%); return on assets equals 1.33%, slightly below the industry peer mean (1.579%). Total debt stands at $16,105,000,000 with debt-to-equity of 0.714, just below the industry peer mean (0.807). Debt-to-EBITDA reads 8.31x, indicating elevated leverage relative to operating earnings and a sensitivity to continued margin pressure.

Earnings growth shows deterioration: earnings growth QoQ fell ~93.34% and YoY fell ~78.30%, reflecting the sharp short-run swing in profitability even as revenue expands. Asset turnover at 0.6527 sits above the industry peer mean (0.4170), indicating efficient revenue generation from asset base despite margin erosion.

Valuation summary: WMDST values the stock as under-valued. Supporting that valuation: a P/B around 1.32 (below the industry peer mean 2.09), a P/E about 23.97, and a high free-cash-flow yield (11.49%) which together suggest significant cash-backed value. Offsetting that view: persistent margin decline, steep QoQ earnings deterioration, and elevated debt-to-EBITDA create risk to near-term earnings sustainability.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2026-06-30
REPORT DATE: 2026-07-28
NEXT REPORT DATE: 2026-10-27
CASH FLOW  Begin Period Cash Flow 21.4 B
 Operating Cash Flow 3.6 B
 Capital Expenditures -174.00 M
 Change In Working Capital 2.1 B
 Dividends Paid
 Cash Flow Delta 2.9 B
 End Period Cash Flow 24.3 B
 
INCOME STATEMENT REVENUE
 Total Revenue 53.6 B
 Forward Revenue 8.1 B
COSTS
 Cost Of Revenue 49.0 B
 Depreciation 139.0 M
 Depreciation and Amortization 300.0 M
 Research and Development
 Total Operating Expenses 52.4 B
PROFITABILITY
 Gross Profit 4.6 B
 EBITDA 1.9 B
 EBIT 1.6 B
 Operating Income 1.2 B
 Interest Income
 Interest Expense 153.0 M
 Net Interest Income -153.00 M
 Income Before Tax 1.5 B
 Tax Provision 399.0 M
 Tax Rate 26.9 %
 Net Income 1.1 B
 Net Income From Continuing Operations 1.1 B
EARNINGS
 EPS Estimate 1.08
 EPS Actual 2.51
 EPS Difference 1.43
 EPS Surprise 132.407 %
 Forward EPS 1.33
 
BALANCE SHEET ASSETS
 Total Assets 83.0 B
 Intangible Assets 15.0 B
 Net Tangible Assets 7.5 B
 Total Current Assets 46.7 B
 Cash and Short-Term Investments 27.1 B
 Cash 24.2 B
 Net Receivables 18.1 B
 Inventory
 Long-Term Investments 2.9 B
LIABILITIES
 Accounts Payable 18.0 B
 Short-Term Debt 75.0 M
 Total Current Liabilities 40.8 B
 Net Debt
 Total Debt 16.1 B
 Total Liabilities 60.4 B
EQUITY
 Total Equity 22.6 B
 Retained Earnings 11.3 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 45.67
 Shares Outstanding 493.987 M
 Revenue Per-Share 108.46
VALUATION
 Market Capitalization 29.7 B
 Enterprise Value 18.8 B
 Enterprise Multiple 9.682
Enterprise Multiple QoQ 113.768 %
Enterprise Multiple YoY -87.636 %
Enterprise Multiple IPRWA high: 87.909
mean: 34.227
median: 32.178
CNC: 9.682
low: 9.161
 EV/R 0.35
CAPITAL STRUCTURE
 Asset To Equity 3.679
 Asset To Liability 1.375
 Debt To Capital 0.417
 Debt To Assets 0.194
Debt To Assets QoQ -3.803 %
Debt To Assets YoY -4.64 %
Debt To Assets IPRWA high: 0.838
mean: 0.375
median: 0.301
CNC: 0.194
low: 0.006
 Debt To Equity 0.714
Debt To Equity QoQ -6.574 %
Debt To Equity YoY 11.296 %
Debt To Equity IPRWA high: 1.375
mean: 0.807
median: 0.748
CNC: 0.714
low: 0.011
PRICE-BASED VALUATION
 Price To Book (P/B) 1.318
Price To Book QoQ 48.748 %
Price To Book YoY 105.646 %
Price To Book IPRWA high: 7.829
mean: 2.092
median: 1.767
CNC: 1.318
low: -0.321
 Price To Earnings (P/E) 23.974
Price To Earnings QoQ 109.344 %
Price To Earnings YoY -126.209 %
Price To Earnings IPRWA high: 133.945
mean: 48.954
median: 45.322
CNC: 23.974
low: -16.66
 PE/G Ratio -0.939
 Price To Sales (P/S) 0.555
Price To Sales QoQ 46.0 %
Price To Sales YoY 54.013 %
Price To Sales IPRWA high: 11.857
mean: 2.384
median: 1.655
CNC: 0.555
low: 0.158
FORWARD MULTIPLES
Forward P/E 42.333
Forward PE/G -1.659
Forward P/S 3.755
EFFICIENCY OPERATIONAL
 Operating Leverage -3.789
ASSET & SALES
 Asset Turnover Ratio 0.653
Asset Turnover Ratio QoQ 3.186 %
Asset Turnover Ratio YoY 16.117 %
Asset Turnover Ratio IPRWA high: 1.051
CNC: 0.653
median: 0.419
mean: 0.417
low: 0.156
 Receivables Turnover 2.857
Receivables Turnover Ratio QoQ 7.361 %
Receivables Turnover Ratio YoY 28.935 %
Receivables Turnover Ratio IPRWA high: 7.49
mean: 3.742
median: 3.723
CNC: 2.857
low: 0.6
 Inventory Turnover
Inventory Turnover Ratio QoQ
Inventory Turnover Ratio YoY
Inventory Turnover Ratio IPRWA
 Days Sales Outstanding (DSO) 31.935
CASH CYCLE
 Cash Conversion Cycle Days (CCC) -3.834
Cash Conversion Cycle Days QoQ -178.591 %
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 133.289
median: 17.698
mean: 13.096
CNC: -3.834
low: -56.959
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 9.041
 CapEx To Revenue -0.003
 CapEx To Depreciation -1.252
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 38.6 B
 Net Invested Capital 38.7 B
 Invested Capital 38.7 B
 Net Tangible Assets 7.5 B
 Net Working Capital 5.9 B
LIQUIDITY
 Cash Ratio 0.664
 Current Ratio 1.145
Current Ratio QoQ 1.952 %
Current Ratio YoY 4.322 %
Current Ratio IPRWA high: 2.421
CNC: 1.145
mean: 1.052
median: 0.866
low: 0.846
 Quick Ratio
Quick Ratio QoQ
Quick Ratio YoY
Quick Ratio IPRWA
COVERAGE & LEVERAGE
 Debt To EBITDA 8.306
 Cost Of Debt 0.689 %
 Interest Coverage Ratio 10.712
Interest Coverage Ratio QoQ -22.367 %
Interest Coverage Ratio YoY -2193.251 %
Interest Coverage Ratio IPRWA high: 26.066
CNC: 10.712
mean: 6.327
median: 6.254
low: -4.266
 Operating Cash Flow Ratio 0.095
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO) 35.768
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 2.263 %
 Revenue Growth 7.278 %
Revenue Growth QoQ 1554.091 %
Revenue Growth YoY 59.886 %
Revenue Growth IPRWA high: 9.387 %
CNC: 7.278 %
median: 3.075 %
mean: 1.519 %
low: -4.983 %
 Earnings Growth -25.519 %
Earnings Growth QoQ -93.34 %
Earnings Growth YoY -78.298 %
Earnings Growth IPRWA high: 108.333 %
median: 0.389 %
mean: -4.425 %
CNC: -25.519 %
low: -112.5 %
MARGINS
 Gross Margin 8.587 %
Gross Margin QoQ -22.834 %
Gross Margin YoY 42.028 %
Gross Margin IPRWA high: 96.512 %
mean: 28.905 %
median: 14.844 %
CNC: 8.587 %
low: 7.168 %
 EBIT Margin 3.059 %
EBIT Margin QoQ -32.487 %
EBIT Margin YoY -1818.539 %
EBIT Margin IPRWA high: 25.559 %
mean: 7.683 %
median: 4.462 %
CNC: 3.059 %
low: -4.917 %
 Return On Sales (ROS) 2.236 %
Return On Sales QoQ -39.989 %
Return On Sales YoY -370.375 %
Return On Sales IPRWA high: 23.787 %
mean: 8.646 %
median: 4.433 %
CNC: 2.236 %
low: -2.862 %
CASH FLOW
 Free Cash Flow (FCF) 3.4 B
 Free Cash Flow Yield 11.492 %
Free Cash Flow Yield QoQ -47.647 %
Free Cash Flow Yield YoY 27.945 %
Free Cash Flow Yield IPRWA CNC: 11.492 %
high: 6.209 %
mean: 2.071 %
median: 1.947 %
low: -4.3 %
 Free Cash Growth -18.003 %
Free Cash Growth QoQ -101.023 %
Free Cash Growth YoY -222.544 %
Free Cash Growth IPRWA high: 293.51 %
median: 23.352 %
mean: -17.916 %
CNC: -18.003 %
low: -438.717 %
 Free Cash To Net Income 3.131
 Cash Flow Margin 7.23 %
 Cash Flow To Earnings 3.551
VALUE & RETURNS
 Economic Value Added 0.03
 Return On Assets (ROA) 1.329 %
Return On Assets QoQ -31.916 %
Return On Assets YoY -555.137 %
Return On Assets IPRWA high: 4.836 %
mean: 1.579 %
CNC: 1.329 %
median: 1.176 %
low: 0.129 %
 Return On Capital Employed (ROCE) 3.879 %
 Return On Equity (ROE) 0.048
Return On Equity QoQ -32.759 %
Return On Equity YoY -623.944 %
Return On Equity IPRWA high: 0.177
CNC: 0.048
mean: 0.043
median: 0.037
low: -0.05
 DuPont ROE 4.96 %
 Return On Invested Capital (ROIC) 3.099 %
Return On Invested Capital QoQ -29.408 %
Return On Invested Capital YoY -2125.49 %
Return On Invested Capital IPRWA high: 7.881 %
mean: 3.372 %
CNC: 3.099 %
median: 2.555 %
low: -0.608 %

Six-Week Outlook

Expect range-bound price action into the next six weeks with bias toward consolidation and potential short-term weakness. Technicals favor consolidation: low ADX, conflicting DI signals, MACD improving but below its signal line, MRO signaling short-term overextension, and RSI cooling. Key technical support sits near the $61.16 super-trend lower level and the lower Bollinger band area (~$64.4); upside faces resistance near the 20-day band and the analyst price-target mean (~$73.36). Fundamentals provide a valuation tailwind through strong cash generation, but margin and earnings momentum could trigger transient pullbacks if quarterly operational pressures persist.

About Centene Corporation

Centene Corporation (NYSE:CNC) delivers comprehensive healthcare services, primarily targeting under-insured and uninsured populations across the United States. Established in 1984 and based in St. Louis, Missouri, Centene develops a wide array of health plans through its Medicaid, Medicare, and Commercial segments. The Medicaid segment offers expanded health plans, children’s health insurance programs, and long-term services. In the Medicare segment, Centene addresses the needs of seniors with special needs plans, Medicare supplements, and prescription drug plans. The Commercial segment provides marketplace insurance products for individuals and businesses, ensuring extensive access to healthcare services. Centene actively participates in government healthcare contracts, including the TRICARE program for military families, highlighting its dedication to diverse communities. The company also manages clinical healthcare services, pharmacies, and provides dental and speech therapy, promoting a holistic healthcare approach. By collaborating with primary and specialty care physicians, hospitals, and ancillary providers, Centene aims to deliver personalized, high-quality care to millions of Americans, emphasizing innovation and community well-being.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.